The Global Opioids Market was valued at approximately USD 19,869 million in 2020, and it is expected to reach USD 24,435 million in 2026 with a CAGR of 3.5% over the forecast period.
Globally, the COVID-19 pandemic showed many negative effects across the medical spectrum which include a decrease in face-to-face appointments and an increase in telehealth visits. The COVID-19 pandemic has also resulted in a period of isolation, to maintain sufficient capacity in hospitals and to reduce the spread of the virus. Adding to that the chronic pain was one of the hardest-hit field from the COVID-19 pandemic leaving many patients overburdened with their chronic pain and their on-going treatment delayed. For instance, according to a research article by Rajendra K Sahoo et a., published in Indian Journal of Anesthesia 2020, the study results found that 63.16% of pain physicians had the fear of spreading or contracting disease to patient family members, 26.79% had impaired sleep, 1.43% physicians were feeling depressed and 8.14% had feelings of anxiety.
Some of the other major factors driving the market growth include the increasing prevalence of diseases that cause chronic pain, such as cancer, arthritis, lower back pain, fibromyalgia and postsurgical pain, inclination toward extended release formulations from immediate release of opioids and rising focus on abuse-deterrent formulation (ADF) by generic manufacturers.
Opioids are considered as most effective drugs for the management of pain. Moreover, their use in the management of chronic pain is considered to be standard practice in most parts of the world. Due to an increase in the burden of medical ailments, the Opioids market is expected to grow over the forecast period.
Furthermore, opioids play a key role in post-operative settings to provide adequate analgesia. As per the Center for Disease Control and Prevention 2020, over 32.5 million patients were affected by osteoarthritis in the United States. In United Kingdom, there is a steady increasing rate of osteoarthritis. As per Versus Arthritis, in 2019, it was estimated that over 18% of people who were above 45 year of age in England had osteoarthritis of the knee.
According to a research article by Eugenio Cavalli et a., published in International Journal of Immunopathology and Pharmacology 2019, globally, the prevalence of neuropathic pain among general population was estimated to be between 3%-17%. Therefore, opioid therapy is the mainstay of orthopedic treatment of patients with moderate to severe pain, and this helps to drives the overall growth of the market. However, factors such as advent and legalization of cannabis as an alternative to opioids and prescription drug abuse is expected to impede market growth over the forecast period.
Key Market Trends
Strong Agonists are Expected to Hold Significant Market Share in the Receptor Binding Segment
An agonist is a drug molecule that triggers certain receptors in the brain. This agonist produces significant physiological/pharmacological response when only a relatively small number of receptors are occupied, i.e. the drug has high intrinsic activity. Some of the strong agonist opioids include Fentanyl, morphine, dihydromorphinone, meperidine, oxycodone, and oxymorphone.
Globally, COVID-19 has created a health crisis. During the COVID-19 pandemic, globally, health agencies were engaged in the prevention of infection and providing services to COVID-19 patients. This has led to the cancellation of elective surgeries, elective consultations which showed effect on pain services by hospitals and pain clinics.
Methadone is a strong agonist which is found to be an effective treatment for addiction to opioid drugs (such as heroin). Strong agonist bind tightly to opioid receptors which undergo significant conformational changes.
Globally, there are many people who experience pain in their daily lives. For instance, as per Chronic Pain Association of Canada (CPAC) 2019 report, estimates that chronic pain patients were experiencing a decline quality of life with increasing pain. Moreover, between 17-31% of people report chronic pain. 50% percent of hospitalized patients report acute pain of moderate to severe intensity. It was estimated that annual direct medical costs for chronic pain management found to be between USD 10,000-14,000 per patient.
The market players are adopting various strategies such as product approvals and developments to expand their product portfolio, expansions, collaborations and mergers to increase market share. For instance, in November 2018, AcelRx Pharmaceuticals, Inc. received US FDA approval for DSUVIA (Dsuvia is a opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 times as potent as morphine) for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opioid analgesic. Thus, owing to above mentioned factors it is expected to drive the segment growth in near future.
North America Dominates the Market and is Expected to Continue to Dominate in the Forecast Period
The major factors driving the market growth in North America region include rising incidence of orthopedic diseases, growing prevalence of chronic diseases such as cancer and diabetes and rise in disposable income and surge in geriatric population along with presence of key market players in the region.
In United States, the COVID-19 pandemic forced healthcare systems to redistribute healthcare resources towards COVID-19 dedicated sites and intensive care units. During the COVID-19 pandemic 2020, chronic pain services which were non-urgent, outpatient and elective interventional procedures have been reduced or interrupted during the COVID-19 pandemic in order to reduce the risk of viral spread.
According to a research article by Filomena Puntillo et al., published in Best Practice and Research: Clinical Anesthesiology Journal 2020, Chronic pain populations remain isolated with consequent social and psychological impact. The shutdown of pain services due to lockdown imposed by United States government during the COVID-19 pandemic has affected chronic pain management.
The population of cancer survivors in the United States is growing rapidly with increasing cancer pain patients which is boosting the market growth. For instance, according to a research article by Changchuan Jiang et al., published in JAMA Oncology Journal 2019, as per study results, among 4,526 cancer survivors, 1,648 subjects reported to have chronic pain and 768 subjects to have high-impact chronic pain (HICP), representing approximately 5.39 million and 2.51 million cancer survivors, respectively.
In addition, as per government of Canada, in Canada, in 2019, around 7.63 million people had chronic pain. In Canada, Chronic pain had significant impacts on mental and physical health, family and community life, and the economy, with the total direct and indirect cost of USD 38.3 to USD 40.4 billion in 2019.
Morphine and Codeine are the most commonly prescribed opioids for cancer pain. In 2018, the United States Food and Drug Administration launched the 2018 Strategic Policy Roadmap, which aims at reducing the misuse and abuse of opioid drugs. Thus, owing to above mentioned factors it is expected to show significant market growth over the forecast period.
The Opioids Market is fragmented competitive. The market consists of several players. However, with the rising usage of opioids in medicines, more companies are trying to enter this market, especially in the emerging markets. However, strict laws and stringent regulatory policies are deterring market penetration by small- and mid-sized companies. Sone of the market players include Teva Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, Purdue Pharmaceuticals L.P. and others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain
- 4.2.2 Inclination toward Extended Release Formulations from Immediate Release of Opioids
- 4.2.3 Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
- 4.3 Market Restraints
- 4.3.1 Advent and Legalization of Cannabis as an Alternative to Opioids
- 4.3.2 Prescription Drug Abuse
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Product Type
- 5.1.1 Codeine
- 5.1.2 Fentanyl
- 5.1.3 Morphine
- 5.1.4 Meperidine
- 5.1.5 Methadone
- 5.1.6 Other Product Types
- 5.2 By Receptor Binding
- 5.2.1 Strong Agonist
- 5.2.2 Mild to Moderate Agonist
- 5.3 By Application
- 5.3.1 Pain Management
- 126.96.36.199 Cancer Pain
- 188.8.131.52 Neuropathic Pain
- 184.108.40.206 Osteoarthritis Pain
- 220.127.116.11 Other Pain Managements
- 5.3.2 Cold and Cough
- 5.3.3 Diarrhoea
- 5.3.4 Other Applications
- 5.4 Geography
- 5.4.1 North America
- 18.104.22.168 United States (By Product Type, By Receptor Binding and By Application)
- 22.214.171.124 Canada (By Product Type, By Receptor Binding and By Application)
- 126.96.36.199 Mexico (By Product Type, By Receptor Binding and By Application)
- 5.4.2 Europe
- 188.8.131.52 Germany (By Product Type, By Receptor Binding and By Application)
- 184.108.40.206 United Kingdom (By Product Type, By Receptor Binding and By Application)
- 220.127.116.11 France (By Product Type, By Receptor Binding and By Application)
- 18.104.22.168 Italy (By Product Type, By Receptor Binding and By Application)
- 22.214.171.124 Spain (By Product Type, By Receptor Binding and By Application)
- 126.96.36.199 Rest of Europe (By Product Type, By Receptor Binding and By Application)
- 5.4.3 Asia-Pacific
- 188.8.131.52 China (By Product Type, By Receptor Binding and By Application)
- 184.108.40.206 Japan (By Product Type, By Receptor Binding and By Application)
- 220.127.116.11 India (By Product Type, By Receptor Binding and By Application)
- 18.104.22.168 Australia (By Product Type, By Receptor Binding and By Application)
- 22.214.171.124 South Korea (By Product Type, By Receptor Binding and By Application)
- 126.96.36.199 Rest of Asia-Pacific (By Product Type, By Receptor Binding and By Application)
- 5.4.4 Middle East and Africa
- 188.8.131.52 GCC (By Product Type, By Receptor Binding and By Application)
- 184.108.40.206 South Africa (By Product Type, By Receptor Binding and By Application)
- 220.127.116.11 Rest of Middle East and Africa (By Product Type, By Receptor Binding and By Application)
- 5.4.5 South America
- 18.104.22.168 Brazil (By Product Type, By Receptor Binding and By Application)
- 22.214.171.124 Argentina (By Product Type, By Receptor Binding and By Application)
- 126.96.36.199 Rest of South America (By Product Type, By Receptor Binding and By Application)
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Mallinckrodt Pharmaceuticals LLC
- 6.1.2 Purdue Pharmaceuticals L.P.
- 6.1.3 Rhodes Technologies LP
- 6.1.4 Sun Pharmaceutical Industries Ltd
- 6.1.5 Teva Pharmaceuticals Inc.
- 6.1.6 Vertice Pharma LLC
- 6.1.7 Johnson and Johnson
- 6.1.8 AbbVie Inc (Allergan PLC)
- 6.1.9 Hikma Pharmaceuticals PLC
- 6.1.10 Endo Pharmaceuticals Inc.
- 6.1.11 Zyla Life Sciences (Egalet Corporation)
- 6.1.12 Amneal Pharmaceuticals Inc.
- 6.1.13 Pfizer Inc
- 6.1.14 AcelRx Pharmaceuticals, Inc
- 6.1.15 Archimedes Pharma
- 6.1.16 Cadila Healthcare (Sentynl Therapeutics, Inc.)
- 6.1.17 Alcaliber S.A.
- 6.1.18 Verve Health Care LTD.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS